ストックスクリーナーアプリを入手
3.58
0.28%
-0.010
アフターアワーズ：
3.58
Bolt Biotherapeutics Inc (BOLT) 最新ニュース
Bolt Biotherapeutics CEO Quinn sells $58,402 in stock By Investing.com - Investing.com South Africa
Bolt Biotherapeutics CEO Quinn sells $58,402 in stock - Investing.com
Bolt Biotherapeutics COO Grant Yonehiro sells $43,806 in company shares By Investing.com - Investing.com Nigeria
Bolt Biotherapeutics senior VP Nemec sells $26,072 in shares By Investing.com - Investing.com Canada
Bolt Biotherapeutics COO Grant Yonehiro sells $43,806 in company shares - Investing.com
Bolt Biotherapeutics (BOLT) CEO logs stock sales and an ESPP buy - Stock Titan
Bolt Biotherapeutics (BOLT) Climbs 6.43% to $3.56 as Shares Test Upper RangeMcClellan Oscillator - careplusvn.com
BOLT - Finviz
BOLT Q2 2026 Earnings: Wider-than-Expected Per-Share Loss of -$4.57 Highlights Cost PressuresEBITDA Margin Trends - vinanet.vn
Bolt Biotherapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update - Barchart.com
BOLT Q2 2026 Earnings: Widened Loss of -$4.57 Per Share Misses Consensus by 32.3%Return On Assets - vinanet.vn
Bolt Biotherapeutics . Stock Price Forecast. Should You Buy BOLT? - StockInvest.us
Bolt Biotherapeutics (BOLT) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Bolt (BOLT) Snapshot: Finishes 2.05% Higher at $3.74 for the Current Session; Next Test: the Supplied Trading Band Runs From $3.55 to $3.93 under the Current SnapshotDividend Growth Stocks - siam.in
Bolt (BOLT) Levels: Records a 2.60% Increase to $3.26 in the Current Update; Price Context: the Near-Term Reference Band Stretches From $3.10 to $3.42 in the Current UpdateTrend Following Picks - vinanet.vn
Price Context: the Near-Term Reference Band Stretches From $3.10 to $3.42 in the Current UpdateRunaway Gap - dars.gov.et
Bolt (BOLT) Quarterly Figures: The EPS Result Is Below Expectation; Price Reaction: Shares Fall 0.72%Buyback Announcement Report - vinanet.vn
Bolt Biotherapeutics (BOLT) Gains 4.36% as Shares Test Key Technical LevelsLarge Cap Trends - Vinanet
Renaissance Technologies (BOLT) reports 5.13% ownership stake in Bolt Biotherapeutics - Stock Titan
Bolt Biotherapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - The Manila Times
Bolt Biotherapeutics, Inc. (BOLT) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
BOLT Looks 49.0% Undervalued on GF Value™ Despite Clinical-Stage Challenges - GuruFocus
Bolt Biotherapeutics Inc.: Q2 Earnings Snapshot - KHOU
Bolt Biotherapeutics Q2 net loss narrows on restructuring and lower research activity - TradingView
Bolt Biotherapeutics, Inc. Q2 2026: Revenue $5K, Net loss $(7.72M), EPS $(4.57) — 10-Q Summary - TradingView
BOLT: BDC-4182 trial progresses as cash runway extends into Q1 2027 amid lower Q2 expenses - TradingView
Bolt Biotherapeutics (BOLT) flags going concern risk as losses fall and cash nears $18M - Stock Titan
Press Release: Bolt Biotherapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - Moomoo
Bolt Biotherapeutics (BOLT) Advances 4.65% as Buyers Defend Key SupportSeasonality Effect - careplusvn.com
Bolt Biotherapeutics Inc (BOLT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
BOLT Q2'26 Earnings: revenue estimate is 500.00K USD - TradingView
Bolt Biotherapeutics (BOLT) Slips 1.24% to $3.99; Resistance at $4.19 Caps UpsideIV Expansion Alert - dars.gov.et
BOLT|Bolt Biotherapeutics Inc|Price:3.580|Chg%:-0.010 - TradingKey
Bolt Biotherapeutics, Inc. Revenue Breakdown – NASDAQ:BOLT - TradingView
Bolt Biotherapeutics Inc (BOLT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Bolt Biotherapeutics Inc (BOLT) Valuation: PE, PB & Fair Value Analysis - tradingkey.com
Bolt Biotherapeutics Inc (BOLT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
TradingKey - TradingKey
Bolt Biotherapeutics Inc (BOLT) Cash Flow - TradingKey
BOLT|Bolt Biotherapeutics Inc|Price:3.830|Chg%:+0.110 - TradingKey
Bolt Biotherapeutics Inc (BOLT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Bolt Biotherapeutics Inc. (BOLT) Q1 2026 Earnings: Wider-than-Expected Loss Amid Clinical Development ProgressTech Earnings Analysis - careplusvn.com
Bolt Biotherapeutics Inc. (BOLT) Q1 2026 Earnings: Wider-than-Expected Loss as Development Stage Company Reports No RevenuePreliminary Results - careplusvn.com
Bolt Biotherapeutics (BOLT) Climbs 7% as Support HoldsDark Pool Volume - careplusvn.com
Bolt Biotherapeutics (BOLT) Gains Momentum: Stock Rises 1.82% Amid Potential Biotech RallyZigzag Correction - dars.gov.et
Bolt Biotherapeutics Inc (BOLT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
A419U9 Forecast — Price Target — Prediction for 2027 - TradingView
BOLT Forecast — Price Target — Prediction for 2027 - TradingView
Bolt Biotherapeutics, Inc. Actuals & Estimates (MUN:6LP0) - TradingView
Enterprise value to revenue forward of Bolt Biotherapeutics, Inc. – NASDAQ:BOLT - TradingView
Revenue per share of Bolt Biotherapeutics, Inc. – FWB:6LP0 - TradingView
6LP0 Forecast — Price Target — Prediction for 2027 - TradingView
Price to book forward of Bolt Biotherapeutics, Inc. – NASDAQ:BOLT - TradingView
Bolt Biotherapeutics (BOLT) Slides 5% in Heavy Trading as Key Support Level ApproachesVOLD Alert - dars.gov.et
Bolt Biotherapeutics Inc (BOLT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Bolt Biotherapeutics Inc (BOLT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Bolt Biotherapeutics Inc (BOLT) Institutional Confidence - TradingKey
Bolt Biotherapeutics Inc. (BOLT) Q1 2026 Earnings: Large EPS Miss Reflects Continued R&D InvestmentEPS Growth Rate - newsline.com
Bolt Biotherapeutics Holds 2026 Annual Stockholder Meeting - TipRanks
Bolt Biotherapeutics (BOLT) director receives 5,000 stock options at $4.43 exercise price - Stock Titan
3.06%
2.55%
大文字化:
|
ボリューム (24 時間):